Indian Pharma sector to grow at slower pace

The Indian pharmaceutical industry is expected to grow at a sluggish pace due to slower growth in the US market, rise in competition and saturated adoption of generics as per rating agency, the ICRA, a Moody’s Investors Service company.

The growth in the US market has fallen to 9% in the first half of 2016-17 and is expected to be under further pressure in the future, noted a posting on the website of Brand India Pharma, an initiative led by Pharmexcil (Pharmaceutical Export Promotion Council) and IBEF (India Brand Equity Foundation) under the aegis of the Department of Commerce, Government of India.

Greater regulatory checking, consolidation of the supply chain resulting in pricing pressure, as well rise in R&D expenses are, however, impacting the profitability of Indian pharmaceutical companies.